Thyroid-associated ophthalmopathy. Pathogenesis, clinical presentation and examination, stage-dependent therapy;Endokrine orbitopathie. Pathogenese, klinisches bild und untersuchung, stadienabhängige therapie

Ophthalmologe

Volumn 100, Issue 10, 2003, Pages 857-880

  Eckstein, A ^a   Esser, J ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

Antiinflammatory therapy; Clinical activity score; Severity score; Surgical therapy; Thyroid associated ophthalmopathy; TSH receptor antibodies

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; IMMUNOSUPPRESSIVE AGENT; SOMATOSTATIN DERIVATIVE; STEROID; THYROTROPIN RECEPTOR ANTIBODY;

CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL FACTOR; EXTRAOCULAR MUSCLE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HUMAN; PATHOGENESIS; PROSPECTIVE STUDY; REVIEW; SMOKING; STRESS; TREATMENT INDICATION; ORBIT DISEASE;

GRAVES DISEASE; HUMANS; ORBITAL DISEASES;

EID: 0242386602     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-003-0873-4     Document Type: Review

References (87)

1. Allahabadia A, Heward JM, Nithiyananthan R et al. (2001) MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease. Lancet 358:984-985
2. Bartalena L, Marcocci C, Chiovato L et al. (1983) Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56:1139-1144
3. Bartalena L, Marcocci C, Bogazzi F et al. (1989) Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349-1352
4. Bartalena L, Martino E, Marcocci C et al. (1989) More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 12:733-737
5. Bartalena L, Marcocci C, Bogazzi F et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78
6. Bartalena L, Marcocci C, Tanda ML et al. (1998) Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 129:632-635
7. Bartley GB, Fatourechi V, Kadrmas EF et al. (1995) Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:426-434
8. Bartley GB, Fatourechi V, Kadrmas EF et al. (1996) Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284-290
9. Batch JA, Lepre F (1990) Early diagnosis of Graves' optic neuropathy using visual evoked responses. Postgrad Med J 66:664-666
10. Benker G, Kahaly GJ, Reinwein D (1999) What can the European Multicenter Trial on the treatment of Grayes' disease with antithyroid drugs teach us about the course of thyroid-associated orbitopathy (TAO)? European Multicenter Trial Group. Exp Clin Endocrinol Diabetes 1075B:IM:5186-5189
11. Boergen KP (1993) Schieloperation in Tropfanästhesie bei endokriner Orbitopathie. Z Prakt Augenheilkd 14:301-305
12. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA (2000) Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 129:618-622
13. Brix TH, Kyvik KO, Christensen K, Hegedus L (2001) Evidence for a major role of heredity in Grave's disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 86:930-934
14. Crisp M, Starkey KJ, Lane C et al. (2000) Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41:3249-3255
15. DeGroot LJ (1997) Radioiodine and the immune system. Thyroid 7:259-264
16. Dickinson AJ, Perros P (2001) Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55:283-303, Review
17. Eckstein A, Fischer M, Krüger C et al. (2002) Behandlung der schweren Endokrinen Orbitopathie mit Optikuskompression. Z Prakt Augenheilkd 23:325-330
18. Eckstein A, Finkenrath A, Esser J et al. (2002) Dry-eye syndrom in patients with thyroid associated ophthalmopathy (TAO) - possible association to TSH- receptor-expression in lacrimal gland. Der Ophthalmologe 99 [Suppl 1]:36
19. Eckstein A, Plicht M, Morgenthaler N et al. (2003) TSH Receptor Antibodies (TSHR-AB) help to predict severity and outcome of thyroid associated ophthalmopathy (TAO). VII International Symposium on Graves' Ophthalmopathy, p 53
20. Eckstein A, Quadbeck B, Mueller G et al. (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy (TAO). Br J Ophthalmol 87:773-776
21. Esser J (1994) Endokrine Orbitopathie - Eingriffe an den äußeren Augenmuskeln. Ophthalmologe 91:3-19
22. Esser J, Eckstein A (1999) Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107 [Suppl 5]:5214-221
23. Esser J (1994) Endokrine Orbitopathie - Eingriffe an den äußeren Augenmuskeln. Ophthalmologe 91:3-19
24. Esser J (1998) Lidretraktion bei Endokriner Orbotopathie: Beeinflussung durch Augenmuskel und Schieloperationen. Orthoptik Pleoptik 22:13-23
25. Garrity JA, Saggau DD, Gorman CA et al. (1992) Torsional diplopia after transantral orbital decompression and extraocular muscle surgery associated with Graves' orbitopathy. Am J Ophthalmol 113:363-373
26. Garrity JA, Fatourechi V, Bergstralh EJ et al. (1993) Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am J Ophthalmol 116:533-547
27. Gerding MN, van der Meer JW, Broenink M et al. (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52:267-271
28. 6erding MN, Prummel MF, Wiersinga WM (2000) Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin parameters. Clin Endocrinol (Oxf) 52:641-646
29. Gerling J, Kommerell G, Henne K et al. (2003) Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 55:182-189
30. Goldberg RA, Perry JD, Hortaleza V, Tong JT (2000) Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthal Plast Reconstr Surg 16:271-277
31. Goldberg RA, Soroudi AE, McCann JD (2003)Treatment of prominent eyes with orbital rim onlay implants: four-year experience. Ophthal Plast Reconstr Surg 19:38-45
32. Gorman CA, Garrity JA, Fatourechi V et al. (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 108:1523-1534
33. Hagg E, Asplund K (1987) Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed) 295:634-635
34. Heufelder A, Weetman A, Ludgate M, Bahn R (2000) Pathogenesis of Graves' ophthalmopathy. In: Prummel M (ed) Recent developments in Graves' Ophthalmopathy. Kluwer Academic Publishers, pp 15-39
35. Heufelder A, Joba W, Heufelder G (2003) Antioxidants in Graves' disease: preliminary results from the Munich endocrine ophthalmopathy prevention study (MOPS). VII International Symposium on Graves' Ophthalmopathy, p 25
36. Kahaly G, Schrezenmeir J, Krause U et al. (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16:415-422
37. Kahaly GJ, Rosler HP, Pitz S, Hommel G (2000) Low-versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 85:102-108
38. Kahaly GJ, Dittmar M, Antunes C et al. (2002) Randomized trial of intravenous versus oral steroid therapy in Graves' Ophthalmpathy. 74th Annual Meeting of the American Thyroid Association, p 159
39. Kalmann R, Mourits MP, van der Pol JP, Koornneef L (1997) Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy. Br J Ophthalmol 81:41-45
40. Kauppinen-Makelin R, Karma A, Leinonen E et al. (2002) High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 80:316-321
41. Kazim M, Goldberg RA, Smith TJ (2002) Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 120:380-386
42. Kennedy DW, Goodstein ML, Miller NR, Zinreich SJ (1990) Endoscopic transnasal orbital decompression. Arch Otolaryngol Head Neck Surg 116:275-282
43. Kendall-Taylor P, Perros P (1998) Clinical presentation of thyroid associated orbitopathy. Thyroid 8:427-428
44. Khoo DH, Ho SC, Seah LL et al. (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9:1175-1180
45. Kommerell G (1992) Neurochirurgische Erweiterung der Augenhöhle zur Behandlung schwerer endokriner Orbitopathien. Z Prakt Augenheilkd 14:307-310
46. Krassas GE, Doumas A, Kaltsas T et al. (1999) Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 9:47-52
47. Krzizok T, Efinger K, Kaufmann H (1993) Dosierbarkeit von Augenmuskeloperationen bei endokriner Orbitopathie. Z Prakt Augenheilkd 14:273-279
48. Kushner BJ (1992) Torsional diplopia after transantral orbital decompression and extraocular muscle surgery associated with Graves' orbitopathy. Am J Ophthalmol 114:239-240
49. Kung AW (1995) Life events, daily stresses and coping in patients with Graves' disease. Clin Endocrinol (Oxf) 42:303-308
50. Kung AW, Michon J, Tai KS, Chan FL (1996) The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 6:381-384
51. Ludgate M, Baker G (2002) Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 127:193-198
52. Marcocci C, Bruno-Bossio G, Manetti L et al. (1999) The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 51:503-508
53. Marquez SD, Lum BL, McDougall IR et al. (2001) Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 51:766-774
54. Michel O, Oberlander N, Neugebauer P et al. (2001) Follow-up of transnasal orbital decompression in severe Graves' ophthalmopathy. Ophthalmology 108:400-404
55. Mourits MP, Koornneef L, Wiersinga WM et al. (1990) Orbital decompression for Graves' ophthalmopathy by inferomedial, by inferomedial plus lateral, and by coronal approach. Ophthalmology 97:636-641
56. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9-14
57. Mourits MP, van Kempen-Harteveld ML, Garcia MB et al. (2000) Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 355:1505-1509
58. Mourits M, Rose G, Garrity J et al. (2000) Surgical managemant of Graves' ophthalmopathy. In: Prummel M (ed) Recent developments in Graves' Ophthalmopathy. Kluwer Academic Publishers, pp 133-169
59. Muller-Forell W, Pitz S, Mann W, Kahaly GJ (1999) Neuroradiological diagnosis in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107 [Suppl 5]:S177-183
60. Noh JY, Hamada N, Inoue Y et al. (2000) Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid 10:809-813
61. Nunery WR, Nunery CW, Martin RT et al. (1997) The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 13:153-160
62. Olivari N (2001) Endokrine Orbitopathie. Chirurgische Therapie. Transpalpebrale Dekompression durch Fettentfernung. Kaden, Heidelberg
63. Paridaens D, Hans K, van Buitenen S, Mourits MP (1998) The incidente of diplopia following coronal and translid orbital decompression in Graves' orbitopathy. Eye 12 (Pt 5):800-805
64. Paridaens DA, Verhoeff K, Bouwens D, van Den Bosch WA (2000) Transconjunctival orbital decompression in Graves' ophthalmopathy: lateral wall approach ab interno. Br J Ophthalmol 84:775-781
65. Perros P, Crombie AL, Kendall-Taylor P (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42:45-50
66. Pfeilschifter J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477-481
67. Plicht M, Morgenthaler N, Esser Jet al. (2002) Clinical Results of antiinflammatory therapy in Graves's ophthalmopathy and autoantibodies to thyroidal antigens. J Endocrinol Invest 25 [Suppl 7]:87
68. Prummel MF, Mourits MP, Berghout A et al. (1989) Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321:1353-1359
69. Prummel MF, Wiersinga WM, Moudts MP et al. (1990) Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150:1098-1101
70. Prummel MF, Mourits MP, Blank L et al. (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 342:949-954
71. Prummel MF, Schaefer U, Hesselmann S et al. (2002) A long-term follow-up study after retro-orbital irradiation for Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 52:192-197
72. Raber W, Kmen E, Waldhausl W, Vierhapper H (2000) Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 142:117-124
73. Rundle FF (1945) Development and course of exophthalmus and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Cli Sci 5:177-194
74. Seiff SR, Tovilla JL, Carter SR, Choo PH (2000) Modified orbital decompression for dysthyroid orbitopathy. Ophthal Plast Reconstr Surg 16:62-66
75. Shine B, Fells P, Edwards OM et al. (1990) Association between Graves' ophthalmopathy and smoking. Lancet 33S:1261-1263
76. Tallstedt L, Lundell G, Torring O et al. (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738
77. Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494-497
78. Traisk F, Tallstedt L (2001) Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction - a pilot study. Acta Ophthalmol Scand 79:585-588
79. Trobe JD (1981) Optic nerve involvement in dysthyroidism. Ophthalmology 88:488-492
80. Villadolid MC, Yokoyama N, Izumi M et al. (1995) Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830-2833
81. Wakelkamp I, Tan H, Saeed P et al. (2002) Is retrobulbar irradiation safe in the long run? The Amstrdam Graves' Ophthalmpathy (GO) follow up study. J Endocrind Invest 25 [Suppl to No 7]:7
82. Wakdkamp I (2003) Surgical or medical decompression as a first line treatment of very severe ophthalmopathy. Vil International Symposium on Graves' Ophthalmopathy, p 26
83. Weetman AP, Holt ME, Campbell AK et al. (1984) Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed) 288:518-520
84. Winsa B, Adami HO, Bergstrom R et al. (1991) Stressful life events and Graves' disease. Lancet 338:1475-1479
85. Winsa B, Rastad J, Akerstrom G et al. (1995) Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy. Eur J Endocrinol 132:406-412
86. Wiersinga WM, Prummel MF, Moufits MP et al. (1991) Classification of the eye changes of Graves' disease. Thyroid 1:357-360
87. Yoshiuchi K, Kumano H, Nomura S et al. (1998) Psychosocial factors influencing the short-term outcome of antithyroid drug therapy in Graves' disease. Psychosom Med 60:592-596